Patented Pediatric Supplement Brand, Amazon + 45K Pharmacies

$14.2M

Revenue

$4.1M

SDE

5.5x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This brand was born over 15 years ago when the founder needed to find a creative way to get his infant to take a foul-tasting supplement their pediatrician prescribed. It is the only supplement in the space with a randomized controlled trial published in a leading peer-reviewed medical journal. Its formulation is protected by a granted US patent, and it is distributed through major national pharmaceutical wholesalers into tens of thousands of pharmacy and hospital locations nationwide. The company operates with the lean structure of an ecommerce business with a small team and approximately 28% of revenue recurring through a base of roughly 29K active subscribers. Concentration on Amazon (65%–70% of revenue) is declining by design as the higher-margin DTC channel grows. Growth requires deploying capital against proven assets. The most immediate lever is subscription optimization. No subscriber-exclusive pricing exists today, no SMS program has been built, and an email database of nearly 49,000 profiles already achieves 64% open rates. Paid social has never been systematically tested against a brand with 4.5-star conversion assets. A physician-influencer program, which the seller identifies as the highest-potential and least capital-intensive opportunity, is producing encouraging early results. Beyond these, the Amazon presence remains US-only, an existing international reseller network provides a beachhead abroad, and three new product lines are already scoped. A tenured team manages day-to-day marketplace, website, operations, and brand functions and is willing to remain. The seller (who is looking to retire) commits to structured transition support, including direct introductions to physician and wholesaler relationships, and the company’s longtime pediatrician Chief Medical Officer is available to continue. The buyer inherits the moat already built, the growth engine already running, and every major lever still waiting to be pulled.

Why we like it

Earnings quality is strong for an ecommerce brand: $4.15M SDE on $14.2M revenue is a 29% margin, with roughly 28% of revenue recurring through 29K subscribers. Recurring supplement consumption plus a 49K email list at 64% open rates gives real visibility into repeat demand, not one-time impulse purchases.
The moat is unusually durable for a consumables brand. A granted US patent on the formulation, a published randomized controlled trial in a peer-reviewed journal, and physician recommendation create switching friction and credibility that most Amazon supplement sellers simply cannot replicate. Distribution into tens of thousands of pharmacies and hospitals is a barrier that took years to build.
Market tailwinds favor this product because pediatric health is non-discretionary. Parents do not cut a pediatrician-recommended supplement for their child in a downturn, which insulates the top line from consumer belt-tightening that hammers discretionary DTC brands.
The operator advantage is enormous because the growth levers are documented and untouched. No subscriber-exclusive pricing, no SMS program, no systematic paid social, US-only Amazon, an existing international reseller beachhead, and three scoped new product lines mean a competent operator can compound this without inventing anything new.
The transition risk is well mitigated. A tenured team is willing to stay, a longtime pediatrician Chief Medical Officer will continue, and the retiring seller commits to introductions to physician and wholesaler relationships that are the real engine of distribution.

How to improve it

Launch subscriber-exclusive pricing and a formal loyalty tier immediately. The listing states no subscriber-exclusive pricing exists today, so even a modest incentive should lift the 29K subscriber base and push recurring revenue above the current 28% share, directly improving retention and LTV.
Build the SMS program from zero within the first 90 days. With a 49K email list already posting 64% open rates, layering SMS on top of proven conversion assets is a low-cost, high-ROI channel that captures replenishment revenue this business is currently leaving on the table.
Scale the physician-influencer program the seller flagged as highest-potential and least capital-intensive. Early results are encouraging, so systematize it with tracked referral codes and structured outreach to convert clinical credibility into a repeatable acquisition engine.
Systematically test paid social against the 4.5-star conversion assets. Paid social has never been run methodically, so a disciplined creative and audience testing budget can diversify acquisition away from Amazon dependence and feed the higher-margin DTC channel.
Turn on international expansion using the existing reseller beachhead and by taking the Amazon presence beyond US-only. These channels already have a foothold, so the incremental cost of activation is low relative to the addressable demand abroad.
Accelerate the three already-scoped new product lines to raise average order value and cross-sell into the existing subscriber and email base. Selling more to a proven, high-trust customer base is far cheaper than acquiring new customers and leverages the brand's clinical positioning.
Deliberately shift channel mix toward DTC to expand blended margin. Amazon is 65% to 70% of revenue and declining by design, so reinvesting DTC gains into owned channels reduces platform risk and captures the margin Amazon fees currently absorb.

Diligence notes

Verify the patent status, scope, and remaining life, plus any freedom-to-operate risk. The formulation patent is central to the moat, so confirm it is granted, enforceable, and not nearing expiration, and understand what happens to defensibility when it lapses.
Scrutinize Amazon concentration and account health. With 65% to 70% of revenue on Amazon, review the seller account standing, category ranking stability, review authenticity for the 4.5-star assets, and any history of suspensions or listing hijacking that could threaten the majority of revenue overnight.
Validate the subscriber and recurring revenue claims. Pull cohort-level retention, churn, and reactivation data behind the 29K subscribers and 28% recurring figure, since supplement subscriptions often show high early churn that materially changes LTV assumptions.
Confirm the wholesaler and pharmacy distribution economics. Understand the terms, margins, chargebacks, and reorder cadence across the 45K pharmacy and hospital locations, and whether that channel is genuinely profitable or a low-margin credibility play propped up by Amazon.
Assess regulatory and labeling risk given the pediatric and clinical positioning. Confirm FDA compliance for supplement claims, that the published RCT supports the marketing language used, and that physician-recommendation claims are substantiated to avoid enforcement exposure.
Quantify the SDE normalization and owner add-backs. At a 5.54x multiple on $4.15M SDE, verify the small team is truly sufficient post-sale, that the retiring seller's role is genuinely replaceable by the tenured team, and that no material owner-performed functions are missing from the cost base.

Source

Originally listed on Quiet Light. View original listing →